Research context (RUO): IGF-1 LR3 and IGF-1 DES are synthetic variants of insulin-like growth factor 1. Both are supplied by Peplife exclusively for in vitro laboratory research (Research Use Only) and are not intended for human or animal use.
IGF-1 LR3 vs IGF-1 DES: the difference explained
The comparison IGF-1 LR3 vs IGF-1 DES comes down to a single question: how does a growth factor escape its own braking system? In blood and tissue, free IGF-1 is almost entirely bound by IGF-binding proteins, which tightly regulate its availability. LR3 and DES solve this in two opposite ways: one adds, the other removes. The result is a difference in half-life of roughly a factor of one hundred, and with it a completely different field of application in research.
The shared problem: IGF-binding proteins
More than ninety percent of circulating IGF-1 is bound to one of the six IGF-binding proteins. That binding protects the molecule from degradation, but at the same time keeps it away from the receptor. For research in which the direct receptor response has to be measured, this is awkward: the actually available concentration is unknown and varies with the tissue. Both variants were designed to remove that variable, but through a different intervention on the molecule.
LR3: adding and substituting
IGF-1 LR3, in full Long R3 IGF-1, combines two modifications. A thirteen-amino-acid extension has been added at the N-terminus, and at position 3 glutamic acid has been replaced by arginine. That substitution dramatically lowers the affinity for the binding proteins, while the extension increases stability. The result is a variant to which the literature attributes a half-life on the order of twenty to thirty hours, compared with about ten minutes for free IGF-1.
DES: removing instead
IGF-1 DES, in full des(1-3)IGF-1, goes the other way: the first three amino acids of the chain have been removed. This too sharply lowers the affinity for the binding proteins, but without lengthening or stabilising the molecule. In cell models the variant is therefore more potent than intact IGF-1. The classic work by Ballard and colleagues described it as a potent derivative. The half-life nevertheless remains short, on the order of minutes to tens of minutes. DES acts hard and briefly; LR3 acts evenly and long.
The two variants side by side
| Feature | IGF-1 LR3 | IGF-1 DES |
|---|---|---|
| Full name | Long R3 IGF-1 | des(1-3)IGF-1 |
| Modification | Thirteen amino acids added, Arg at position 3 | First three amino acids removed |
| Binding to IGFBP | Strongly reduced | Strongly reduced |
| Half-life | Tens of hours | Minutes to tens of minutes |
| Potency in cell models | Comparable to IGF-1 | Higher than intact IGF-1 |
| Suited to | Prolonged, steady exposure | Short, sharp receptor stimulation |
| Most used in | Cell culture and infusion models | Acute stimulation experiments |
Why half-life determines the research model
In cell culture a long half-life is practical: the medium needs refreshing less often and exposure stays stable over days. That is why LR3 is a standard supplement in serum-free culture systems. In models where it is precisely the acute response to a single stimulus that is measured — receptor phosphorylation, signal transduction within a few minutes — a short-acting variant is preferable, because the stimulus is sharply bounded. Anyone comparing the two in the same protocol should therefore not match the concentration but the exposure over time.
Systemic versus local in animal research
On systemic administration in animal models, LR3 produces organ and tissue growth that does not occur with intact IGF-1, or occurs far more weakly, precisely because the inhibitory binding falls away. DES rarely reaches a stable level on systemic administration and is therefore hardly used that way. This makes the literature on the two variants hard to compare with each other: most DES data come from cell models, most LR3 data from culture and infusion models.
The relationship with MGF and other IGF variants
Besides these two synthetic variants, IGF-1 also has natural splice forms. Mechano growth factor, the splice variant that arises in muscle tissue after mechanical loading, is the best known of them. That form acts through a different C-terminal peptide and does not belong in the same comparison; the pillar article on MGF and PEG-MGF covers that route separately.
Both variants in laboratory research: handling and reconstitution
Both are proteins of almost seventy amino acids with three disulfide bridges, and therefore more delicate than the short peptides in the range. They tolerate shaking, repeated freezing and pH extremes poorly; once dissolved, the liquid should be kept refrigerated and in the dark, and the shelf life is shorter than for short peptides. The reconstitution guide sets out the calculation steps and the practicalities of preparation and storage.
Quality & purity
With proteins of this length, purity alone says nothing: the folding and the correct disulfide bridges determine whether the molecule is active. Every relevant batch is independently HPLC-tested by an external laboratory and the certificate of analysis is publicly verifiable per batch, so that the research material demonstrably matches the specified protein. In the pillar article why we rejected a batch you can read how that process works in practice.
Frequently asked questions about IGF-1 LR3 and IGF-1 DES
What is the main difference between IGF-1 LR3 and IGF-1 DES?
LR3 adds an extension and replaces one amino acid, which raises the half-life to tens of hours. DES instead removes the first three amino acids and stays short-acting.
Why do both bypass the IGF-binding proteins?
Because more than ninety percent of free IGF-1 is bound, which makes the concentration available at the receptor unknown and variable. Both modifications strongly lower that binding.
Which variant is more potent in cell models?
In cell culture, DES shows a higher potency than intact IGF-1. LR3 is not so much more potent as present for longer.
Why is LR3 standard in cell culture?
Because of the long half-life, exposure in serum-free medium stays stable for days, which limits the number of medium changes and therefore the variation.
Are these variants approved anywhere?
No. Neither is approved by the EMA, NVWA or FDA; they are supplied exclusively for laboratory research.
Read more & research at Peplife
- Research IGF-1 LR3 at Peplife
- Research IGF-1 DES at Peplife
- View all GH axis peptides
- IGF-1 LR3: the research dossier
- IGF-1 DES: research into the short-acting variant
- MGF and PEG-MGF: the splice route
- Follistatin-344: research into muscle growth regulation
Sources: IGF-1 LR3 — overview · Des(1-3)IGF-1 — overview · Comparative research on IGF analogues, PubMed · IGF-binding proteins and bioavailability, PMC · IGF-1 receptor binding, PMC · PubChem — IGF-1 LR3
Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.
Do you want to characterise both IGF variants side by side in your own model system? We supply IGF-1 LR3 and IGF-1 DES with a batch-specific certificate of analysis and third-party verification.